Cadrenal Therapeutics (CVKD) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order by the CEO, with board members, management, legal counsel, and auditors present virtually.

• The agenda included five business items, with voting instructions and Q&A procedures explained.

Board and executive committee updates

• The board is divided into three classes, with the Class I director's term expiring at this meeting.

• Quang X. Pham was nominated for re-election as Class I director for a three-year term.

Shareholder proposals

• Election of one director for a three-year term.

• Ratification of the independent registered public accounting firm for 2026.

• Approval of an amendment to the 2022 Successor Equity Incentive Plan to increase available shares.

• Approval of issuance of up to 960,000 shares upon exercise of Series C-1 warrants.

• Approval of potential adjournment to solicit further votes if needed.